Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Parkinson Disease

In brief

The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients at early stage of the disease.

Key facts

Study ID

NCT02847650

Run by

Pfizer

People needed

57

Starts

2016-10-17

Expected to finish

2018-01-29

Last updated by the study team

2020-11-23

Who can join

Age: 45 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Females of non-childbearing potential and/or male subjects
• Clinical diagnosis of Parkinson's disease.
• Parkinson's Disease Hoehn \& Yahr Stage I-III inclusive
• Treatment naïve or history of prior incidental treatment with dopaminergic agents for no more than 28 days
• Able to refrain from any Parkinson's disease medication not permitted by the protocol.

You may not qualify if…

• History or presence of atypical Parkinsonian syndrome.
• Severe acute or chronic medical or psychiatric condition or cognitive impairment or laboratory abnormality.
• Any condition possibly affecting drug absorption.
• Participation in other studies involving investigational drug(s), or treatment with any investigational drug within 30 days.

Where it is running

• St Joseph's Hospital and Medical Center, Barrow Neurology Clinics — Phoenix, Arizona, United States
• St. Joseph's Hospital and Medical Center — Phoenix, Arizona, United States
• Parkinson's Disease and Movement Disorders Center of Boca Raton — Boca Raton, Florida, United States
• University of Miami — Miami, Florida, United States
• University of South Florida Carol and Frank Morsani Center for Advanced Health Care — Tampa, Florida, United States
• University of South Florida Faculty Office Building — Tampa, Florida, United States
• University of South Florida — Tampa, Florida, United States
• University of South Florida Parkinson's Disease and Movement Disorders Center — Tampa, Florida, United States
• Atlanta Center for Medical Research — Atlanta, Georgia, United States
• Rush University Medical Center — Chicago, Illinois, United States
• University of Kansas Medical Center — Kansas City, Kansas, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Brigham and Women's Hospital — Boston, Massachusetts, United States
• Asheville Neurology Specialists PA — Asheville, North Carolina, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• University of Toledo, Gardner-McMaster Parkinson Center — Toledo, Ohio, United States
• University of Toledo — Toledo, Ohio, United States
• AS Clinical Research Consultants of North Texas, PLLC — Greenville, Texas, United States
• Baylor College of Medicine — Houston, Texas, United States
• Sentara Neurology Specialists — Virginia Beach, Virginia, United States
• Hopital Henri Mondor — Créteil, France
• Hôpital Henri Mondor — Créteil, France
• CHU de Grenoble Alpes — Grenoble, France
• CHU Grenoble Alpes — La Tronche, France
• Hospital de La Timone — Marseille, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.